Qnovia, a Los Angeles, CA-based pharma company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases, raised $17M in Series A funding.
The round was led by Blue Ledge Capital with participation from DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures.
The company intends to use the funds to advance its NRT drug candidate through an IND submission with the FDA and begin human clinical trials in 2023.
Founded by Mario Danek in 2018 and led by CEO Brian Quigley, Qnovia is a pharma company focused on developing and commercializing proprietary inhalation device technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs. The company’s drug delivery platform, the RespiRx, is an orientation-agnostic, portable vibrating mesh nebulizer that operates in position held by the patient.
FinSMEs
28/09/2022